Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.

Autor: Rodríguez Pérez A; Radiation Oncology Department, Hospital Ruber Internacional, C. de La Masó, 38, 28034, Madrid, Spain. auroraropez@gmail.com., Felip Font E; Medical Oncology Department, Hospital Universitario del Vall d'Hebron, Barcelona, Spain., Chicas-Sett R; Department of Radiation Oncology, ASCIRES Grupo Biomédico, Valencia, Spain., Montero-Luis Á; Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain., de Paz Arias L; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain., González-Del-Alba A; Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., López-Campos F; Radiation Oncology Department, Hospital Ramón y Cajal, Madrid, Spain., López López C; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Hernando Requejo O; Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain., Conde-Moreno AJ; Radiation Oncology Department, Hospital La Fe, Valencia, Spain., Arranz Arija JÁ; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., de Castro Carpeño J; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Apr; Vol. 25 (4), pp. 882-896. Date of Electronic Publication: 2022 Dec 16.
DOI: 10.1007/s12094-022-03011-6
Abstrakt: Oligometastatic disease (OMD) defines a cancer status that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While diagnostic imaging tools have considerably improved in recent years, unidentified micrometastases can still evade current detection techniques, allowing the disease to progress. The various OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of early disease control. In view of increasing OMD detection rates in current real-world clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies might translate into promising treatment options. This expert review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of non-small cell lung cancer and breast cancer (Part I), and prostate cancer and colorectal cancer (Part II), aiming to offer specialists a pragmatic framework to help improve patient management.
(© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
Databáze: MEDLINE
Externí odkaz: